A PKC-beta inhibitor treatment reverses cardiac microvascular barrier dysfunction in diabetic rats.
Wei L1, Yin Z, Yuan Y, Hwang A, Lee A, Sun D, Li F, Di C, Zhang R, Cao F, Wang H.
Author information
1Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China.
Abstract
The PKC-beta inhibitor ruboxistaurin (RBX or LY333531) prevents diabetic renal and retinal microvascular complications. However, the effect of RBX on diabetic cardiac microvascular dysfunction is still unclear. In this study, we aimed to investigate the effects and mechanisms of RBX treatment upon cardiac endothelial barrier dysfunction in high glucose states. We demonstrated RBX treatment suppressed high glucose induced PKC-betaII activation and phosphorylation of beta-catenin in vivo and in vitro experiments. Meanwhile, RBX treatment protected cardiac microvascular barrier function in diabetic animals and monolayer barrier function of cultured cardiac microvascular endothelial cells (CMECs), reproducing the same effect as PKC-betaII siRNA. These results provide new insight into protective properties of PKC-beta inhibitor against cardiac endothelial barrier dysfunction. PKC-beta inhibitor RBX prevented chronic cardiac microvascular barrier dysfunction and improved endothelial cell-cell junctional function in high glucose states.
小核酸转染试剂Entranster™-R4000 已有 223 篇已发表文献
同类研究
- J Ovarian Res. 2026 Jul 31;19(1):330.doi: 10.1186/s13048-026-02215-6. Microfluidic lipid nanoparticles co-delivering siM…
- Front Immunol. 2026 May 29;17:1724930.doi: 10.3389/fimmu.2026.1724930. Machine learning-based identification of an oxida…
- Biomolecules. 2026 May 19;16(5):741.doi: 10.3390/biom16050741. Up-Regulation of the TRPM8 Channel Attenuates TRPC1-Media…
- J Nutr Biochem. 2026 May:151:110261.doi: 10.1016/j.jnutbio.2026.110261. Epub 2026 Jan 6. Dietary phospholipids alleviate…
- FASEB J. 2026 May 15;40(9):e71855.doi: 10.1096/fj.202503895RR. High-Fat Diet Induces Inflammatory Injury in Mice Sertoli…